Davita-Arvin Dialysis is a medicare approved dialysis facility center in Arvin, California and it has 16 dialysis stations. It is located in Kern county at 902 Bear Mountain Blvd, Arvin, CA, 93203. You can reach out to the office of Davita-Arvin Dialysis at (661) 854-3699. This dialysis clinic is managed and/or owned by Davita. Davita-Arvin Dialysis has the following ownership type - Profit. It was first certified by medicare in April, 2014. The medicare id for this facility is 552753 and it accepts patients under medicare ESRD program.
| Name | Davita-Arvin Dialysis |
|---|---|
| Location | 902 Bear Mountain Blvd, Arvin, California |
| No. of Dialysis Stations | 16 |
| Medicare ID | 552753 |
| Managed By | Davita |
| Ownership Type | Profit |
| Late Shifts | No |
| 902 Bear Mountain Blvd, Arvin, California, 93203 | |
| (661) 854-3699 | |
News Archive
Luminex Corporation today announced that it has received FDA clearance for the company's ARIES® System and ARIES HSV 1&2 Assay.
The Pennsylvania Department of Health today announced a new, federally-funded study on the blood disorder Polycythemia vera, or PV, in Bedford, Blair, Cambria and Somerset counties.
Huntington disease (HD) is an inherited neurodegenerative disorder caused by a defect on chromosome four where, within the Huntingtin gene, a CAG repeat occurs too many times. Most individuals begin experiencing symptoms in their 40s or 50s, but studies have shown that significant brain atrophy occurs several years prior to an official HD diagnosis. As a result, the field has sought a preventive treatment that could be administered prior to the development of actual symptoms that might delay the onset of illness.
A groundbreaking new treatment to combat the hospital killer bug MRSA, which is estimated to cause up to 5,000 deaths a year in Britain, is being developed by a University of Sussex scientist.
› Verified 9 days ago
| NPI Number | 1619310513 |
| Organization Name | Arvin Dialysis |
| Doing Business As | Total Renal Care Inc |
| Address | 902 Bear Mountain Blvd Arvin, California, 93203 |
| Phone Number | (661) 854-3699 |
News Archive
Luminex Corporation today announced that it has received FDA clearance for the company's ARIES® System and ARIES HSV 1&2 Assay.
The Pennsylvania Department of Health today announced a new, federally-funded study on the blood disorder Polycythemia vera, or PV, in Bedford, Blair, Cambria and Somerset counties.
Huntington disease (HD) is an inherited neurodegenerative disorder caused by a defect on chromosome four where, within the Huntingtin gene, a CAG repeat occurs too many times. Most individuals begin experiencing symptoms in their 40s or 50s, but studies have shown that significant brain atrophy occurs several years prior to an official HD diagnosis. As a result, the field has sought a preventive treatment that could be administered prior to the development of actual symptoms that might delay the onset of illness.
A groundbreaking new treatment to combat the hospital killer bug MRSA, which is estimated to cause up to 5,000 deaths a year in Britain, is being developed by a University of Sussex scientist.
› Verified 9 days ago
| Dialysis patients with Hemoglobin data | 33 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 12 |
News Archive
Luminex Corporation today announced that it has received FDA clearance for the company's ARIES® System and ARIES HSV 1&2 Assay.
The Pennsylvania Department of Health today announced a new, federally-funded study on the blood disorder Polycythemia vera, or PV, in Bedford, Blair, Cambria and Somerset counties.
Huntington disease (HD) is an inherited neurodegenerative disorder caused by a defect on chromosome four where, within the Huntingtin gene, a CAG repeat occurs too many times. Most individuals begin experiencing symptoms in their 40s or 50s, but studies have shown that significant brain atrophy occurs several years prior to an official HD diagnosis. As a result, the field has sought a preventive treatment that could be administered prior to the development of actual symptoms that might delay the onset of illness.
A groundbreaking new treatment to combat the hospital killer bug MRSA, which is estimated to cause up to 5,000 deaths a year in Britain, is being developed by a University of Sussex scientist.
› Verified 9 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 61 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 545 |
| Percentage of adult patients getting regular hemodialysis at the center | 95 |
| Pediatic patients getting regular hemodialysis at the center | 1 |
| Pediatric patient months included in in Kt/V greater than or eqaul to 1.2 | 4 |
News Archive
Luminex Corporation today announced that it has received FDA clearance for the company's ARIES® System and ARIES HSV 1&2 Assay.
The Pennsylvania Department of Health today announced a new, federally-funded study on the blood disorder Polycythemia vera, or PV, in Bedford, Blair, Cambria and Somerset counties.
Huntington disease (HD) is an inherited neurodegenerative disorder caused by a defect on chromosome four where, within the Huntingtin gene, a CAG repeat occurs too many times. Most individuals begin experiencing symptoms in their 40s or 50s, but studies have shown that significant brain atrophy occurs several years prior to an official HD diagnosis. As a result, the field has sought a preventive treatment that could be administered prior to the development of actual symptoms that might delay the onset of illness.
A groundbreaking new treatment to combat the hospital killer bug MRSA, which is estimated to cause up to 5,000 deaths a year in Britain, is being developed by a University of Sussex scientist.
› Verified 9 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Davita-Arvin Dialysis with elevated calcium levels.
| Patients with hypercalcemia | 61 |
| Hypercalcemia patient months | 563 |
| Patients with Serumphosphor | 67 |
| Patients with Serumphosphor less than 3.5 mg/dL | 10 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 21 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 28 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 22 |
| Patients with Serumphosphor greater than 7 mg/dL | 19 |
News Archive
Luminex Corporation today announced that it has received FDA clearance for the company's ARIES® System and ARIES HSV 1&2 Assay.
The Pennsylvania Department of Health today announced a new, federally-funded study on the blood disorder Polycythemia vera, or PV, in Bedford, Blair, Cambria and Somerset counties.
Huntington disease (HD) is an inherited neurodegenerative disorder caused by a defect on chromosome four where, within the Huntingtin gene, a CAG repeat occurs too many times. Most individuals begin experiencing symptoms in their 40s or 50s, but studies have shown that significant brain atrophy occurs several years prior to an official HD diagnosis. As a result, the field has sought a preventive treatment that could be administered prior to the development of actual symptoms that might delay the onset of illness.
A groundbreaking new treatment to combat the hospital killer bug MRSA, which is estimated to cause up to 5,000 deaths a year in Britain, is being developed by a University of Sussex scientist.
› Verified 9 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 47 |
| Patient months included in arterial venous fistula and catheter summaries | 378 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 72 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 7 |
News Archive
Luminex Corporation today announced that it has received FDA clearance for the company's ARIES® System and ARIES HSV 1&2 Assay.
The Pennsylvania Department of Health today announced a new, federally-funded study on the blood disorder Polycythemia vera, or PV, in Bedford, Blair, Cambria and Somerset counties.
Huntington disease (HD) is an inherited neurodegenerative disorder caused by a defect on chromosome four where, within the Huntingtin gene, a CAG repeat occurs too many times. Most individuals begin experiencing symptoms in their 40s or 50s, but studies have shown that significant brain atrophy occurs several years prior to an official HD diagnosis. As a result, the field has sought a preventive treatment that could be administered prior to the development of actual symptoms that might delay the onset of illness.
A groundbreaking new treatment to combat the hospital killer bug MRSA, which is estimated to cause up to 5,000 deaths a year in Britain, is being developed by a University of Sussex scientist.
› Verified 9 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 50 |
| Hospitalization Rate in facility | 157.2 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 295.4 |
| Hospitalization Rate: Lower Confidence Limit | 87.5 |
News Archive
Luminex Corporation today announced that it has received FDA clearance for the company's ARIES® System and ARIES HSV 1&2 Assay.
The Pennsylvania Department of Health today announced a new, federally-funded study on the blood disorder Polycythemia vera, or PV, in Bedford, Blair, Cambria and Somerset counties.
Huntington disease (HD) is an inherited neurodegenerative disorder caused by a defect on chromosome four where, within the Huntingtin gene, a CAG repeat occurs too many times. Most individuals begin experiencing symptoms in their 40s or 50s, but studies have shown that significant brain atrophy occurs several years prior to an official HD diagnosis. As a result, the field has sought a preventive treatment that could be administered prior to the development of actual symptoms that might delay the onset of illness.
A groundbreaking new treatment to combat the hospital killer bug MRSA, which is estimated to cause up to 5,000 deaths a year in Britain, is being developed by a University of Sussex scientist.
› Verified 9 days ago
The rate of readmission show you whether patients who were being treated regularly at Davita-Arvin Dialysis were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 23.8 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 40.7 |
| Readmission Rate: Lower Confidence Limit | 11.5 |
News Archive
Luminex Corporation today announced that it has received FDA clearance for the company's ARIES® System and ARIES HSV 1&2 Assay.
The Pennsylvania Department of Health today announced a new, federally-funded study on the blood disorder Polycythemia vera, or PV, in Bedford, Blair, Cambria and Somerset counties.
Huntington disease (HD) is an inherited neurodegenerative disorder caused by a defect on chromosome four where, within the Huntingtin gene, a CAG repeat occurs too many times. Most individuals begin experiencing symptoms in their 40s or 50s, but studies have shown that significant brain atrophy occurs several years prior to an official HD diagnosis. As a result, the field has sought a preventive treatment that could be administered prior to the development of actual symptoms that might delay the onset of illness.
A groundbreaking new treatment to combat the hospital killer bug MRSA, which is estimated to cause up to 5,000 deaths a year in Britain, is being developed by a University of Sussex scientist.
› Verified 9 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Davita-Arvin Dialysis get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | .23 (As Expected) |
| SIR: Upper Confidence Limit | 1.12 |
| SIR: Lower Confidence Limit | .01 |
News Archive
Luminex Corporation today announced that it has received FDA clearance for the company's ARIES® System and ARIES HSV 1&2 Assay.
The Pennsylvania Department of Health today announced a new, federally-funded study on the blood disorder Polycythemia vera, or PV, in Bedford, Blair, Cambria and Somerset counties.
Huntington disease (HD) is an inherited neurodegenerative disorder caused by a defect on chromosome four where, within the Huntingtin gene, a CAG repeat occurs too many times. Most individuals begin experiencing symptoms in their 40s or 50s, but studies have shown that significant brain atrophy occurs several years prior to an official HD diagnosis. As a result, the field has sought a preventive treatment that could be administered prior to the development of actual symptoms that might delay the onset of illness.
A groundbreaking new treatment to combat the hospital killer bug MRSA, which is estimated to cause up to 5,000 deaths a year in Britain, is being developed by a University of Sussex scientist.
› Verified 9 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Davita-Arvin Dialysis's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 47 |
| Transfusion Rate in facility | 51.2 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 131.7 |
| Transfusion Rate: Lower Confidence Limit | 22.4 |
News Archive
Luminex Corporation today announced that it has received FDA clearance for the company's ARIES® System and ARIES HSV 1&2 Assay.
The Pennsylvania Department of Health today announced a new, federally-funded study on the blood disorder Polycythemia vera, or PV, in Bedford, Blair, Cambria and Somerset counties.
Huntington disease (HD) is an inherited neurodegenerative disorder caused by a defect on chromosome four where, within the Huntingtin gene, a CAG repeat occurs too many times. Most individuals begin experiencing symptoms in their 40s or 50s, but studies have shown that significant brain atrophy occurs several years prior to an official HD diagnosis. As a result, the field has sought a preventive treatment that could be administered prior to the development of actual symptoms that might delay the onset of illness.
A groundbreaking new treatment to combat the hospital killer bug MRSA, which is estimated to cause up to 5,000 deaths a year in Britain, is being developed by a University of Sussex scientist.
› Verified 9 days ago
The rate of mortality show you whether patients who were being treated regularly at Davita-Arvin Dialysis lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 155 |
| Mortality Rate in facility | 18.4 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 30.3 |
| Mortality Rate: Lower Confidence Limit | 10.3 |
News Archive
Luminex Corporation today announced that it has received FDA clearance for the company's ARIES® System and ARIES HSV 1&2 Assay.
The Pennsylvania Department of Health today announced a new, federally-funded study on the blood disorder Polycythemia vera, or PV, in Bedford, Blair, Cambria and Somerset counties.
Huntington disease (HD) is an inherited neurodegenerative disorder caused by a defect on chromosome four where, within the Huntingtin gene, a CAG repeat occurs too many times. Most individuals begin experiencing symptoms in their 40s or 50s, but studies have shown that significant brain atrophy occurs several years prior to an official HD diagnosis. As a result, the field has sought a preventive treatment that could be administered prior to the development of actual symptoms that might delay the onset of illness.
A groundbreaking new treatment to combat the hospital killer bug MRSA, which is estimated to cause up to 5,000 deaths a year in Britain, is being developed by a University of Sussex scientist.
› Verified 9 days ago
Davita-Arvin Dialysis Location: 902 Bear Mountain Blvd, Arvin, California, 93203 Phone: (661) 854-3699 |
News Archive
Luminex Corporation today announced that it has received FDA clearance for the company's ARIES® System and ARIES HSV 1&2 Assay.
The Pennsylvania Department of Health today announced a new, federally-funded study on the blood disorder Polycythemia vera, or PV, in Bedford, Blair, Cambria and Somerset counties.
Huntington disease (HD) is an inherited neurodegenerative disorder caused by a defect on chromosome four where, within the Huntingtin gene, a CAG repeat occurs too many times. Most individuals begin experiencing symptoms in their 40s or 50s, but studies have shown that significant brain atrophy occurs several years prior to an official HD diagnosis. As a result, the field has sought a preventive treatment that could be administered prior to the development of actual symptoms that might delay the onset of illness.
A groundbreaking new treatment to combat the hospital killer bug MRSA, which is estimated to cause up to 5,000 deaths a year in Britain, is being developed by a University of Sussex scientist.
› Verified 9 days ago